

4 ways to help build strong bones



Available from Symbion, Sigma, API & CH2

Today's issue of PD

Pharmacy Daily today features four pages of news, including our Beauty & Wellness feature, plus a full page from Chemsave.

Consider savings

WHETHER it is catalogue pre-order rebates, dispensary assistance subscriptions or bonus stock, aligning with Chemsave delivers bottom-line benefits for your pharmacy. Learn more on [page five](#).

Send us your pollie pics

WITH election campaigning in full swing, we'd love to hear about the local candidates who have visited your pharmacy. Send photos and an account of what took place to info@pharmacydaily.com.au.

Safer, better hospital prescribing in Qld

QUEENSLAND is introducing state-wide Collaborative Pharmacist Medication Prescribing (CPMP), allowing pharmacists to prescribe certain medicines in collaboration with a doctor or nurse practitioner in both public and private hospitals.

Changes to the *Medicines and Poisons (Medicines) Regulation 2021* will pave the way for the statewide rollout of CPMP.

This includes charting medicines for administration in inpatient settings and prescribing medicines for supply to patients on discharge or in an outpatient setting.

Advanced Pharmacy Australia (AdPha) and the Pharmaceutical Society of Australia (PSA) have welcomed the move and applauded the Queensland Government for its nation-leading reform.

Collaborative prescribing practices are a key pillar of both organisations' patient-centred national advocacy as outlined in AdPha's *Yindymarra 2030* and PSA's vision statement, *Pharmacists*

in 2030.

AdPha President Tom Simpson described the move as a major step forward for healthcare delivery in Queensland.

"It's fantastic to see Queensland officially embrace collaborative prescribing to improve patient outcomes," he said.

"The statewide rollout of CPMP will transform the healthcare system by improving efficiency, freeing up critical medical and nursing capacity, and ensuring safer, higher quality medicines management," he continued.

"Currently, Queensland has limited partnered pharmacist medication charting in a handful of hospitals, and expanding CPMP across the state will unlock significant efficiencies and bring Queensland into line with other leading jurisdictions," he said.

PSA Qld Vice President and Hospital Pharmacy Practice Community of Specialty Interest (CSI) member Hannah Knowles said



better use of pharmacists' scope will mean better hospital care for Queenslanders.

"CPMP is a welcome and progressive step that places patients at the centre of care," Knowles said.

"Evidence from existing partnered charting models shows when pharmacists are actively involved in prescribing, we see fewer medication errors, stronger interdisciplinary communication, and better patient outcomes - particularly during hospital stays and transitions of care." KB

PAIN RELIEF THAT LASTS THE WORKING DAY

With once or twice daily dosing^{1-6*}

*Directions - First Day: Initial Dose 2 capsules. Subsequent Days: 1 capsule once or twice daily. A working day is typically 8-12 hours.

NEW

PHARMACIST ONLY MEDICINE
KEEP OUT OF REACH OF CHILDREN

CELEBRES RELIEF[®]
celecoxib 200 mg

For pain relief from muscle & joint injuries



10 capsules
AUST R 463627



NOW AVAILABLE WITHOUT A PRESCRIPTION FOR PAIN RELIEF FROM MUSCLE AND JOINT INJURIES¹

Indications: Short-term relief of pain from muscle and joint injuries, and period pain. Before recommending please review the full Product Information available from https://medsinfo.com.au/product-information/document/Celebres_Relief_PI

¹The recommended dose is a loading dose of 400 mg then 200 mg once or twice daily, as required for up to 5 days.

References: 1. CELEBRES RELIEF[®] (celecoxib) Product Information. 2. Ekman EF et al. Am J Orthop 2002; 31(8):445-451. 3. Petri M et al. J Rheumatol 2004; 31(8):1614-1620. 4. Ralha LV et al. Revista Brasileira de Medicina 2008; 65(11):378-387. 5. Bertin P et al. J Int Med Res 2003; 31(2):102-112. 6. Cheung R et al. Clin Ther 2007; 29:2498-2510.

CELEBRES RELIEF[®] is a Viatris company trade mark. Copyright © 2025 Viatris Inc. All rights reserved. Viatris Pty Ltd. Millers Point, NSW 2000. ABN: 29 601 608 771. Tel: 1800 274 276. AU-CELE-2025-00018. Feb 2025.





Leafio soars 60%

MEDICAL cannabis wholesaler Leafio says sales have climbed by 60% after less than three years in business, making it Australia's largest distributor of the product.

The company praised the role of pharmacists in driving its growth trajectory, achieved by empowering pharmacies to enhance the patient experience and deliver quality service.

Since its launch in 2022, Leafio now offers more than 1,200 products from 100 brands and receives more than 1,000 new orders per day from its network of 3,500 pharmacies Australia-wide.

The company's three distribution centres in Sydney, Brisbane and Melbourne are now able to facilitate 99% of orders with next-day delivery.

In metro centres, Leafio said accessibility has been boosted further by its same-day delivery service, which allows patients to expedite the order process and quickly and reliably access their prescribed medicines and treatments.

Leafio General Manager Nicole Le Maistre said the company was focused on maintaining its position as the country's leading wholesaler.

"Strategically, we will be seeking to broaden our partnerships and work more closely with pharmacy banner groups and parties.

"We also intend to open a fourth warehouse later this year," Le Maistre said.

Wrong meds lead to falls

PSYCHOTROPIC medicines commonly prescribed for older people in aged care homes to treat mental health conditions may cause loss of balance and lead to unnecessary falls and injuries, with researchers saying the medications need to be reviewed.

Using data from 23 residential aged care facilities in Sydney caring for more than 3,000 older people, the team from the Australian Institute of Health Innovation at Macquarie University found 40% of aged care home residents were given "potentially inappropriate" psychotropic medicines such as benzodiazepines, antipsychotics and antiparkinsonian agents over a two-year period.

They found that 70% of the people who had received such medicines experienced at least one fall, compared with 62% who were not taking the medicines.

While the issue of the risk of falls related to psychotropic medicines has been raised in previous research, the latest study examines medicines that were actually administered to aged care home residents - other studies have only looked at drugs that are prescribed, but these are not always administered.

The study also broke down falls by their level of seriousness.

It showed that 70% of aged care home residents who used potentially inappropriate psychotropic medicines had at least one fall, 54% experienced an injury from a fall and 30% required hospitalisation from a fall.

The authors called for regular



medication reviews in aged care homes "to reduce the unnecessary use of potentially inappropriate medicines".

"Medication reviews can alert clinicians and other care staff to a resident who may have been on a medication longer than the recommended time," said the paper's first author, Narjis Batool.

Aged care facilities could consider introducing training to help staff recognise people at risk of a fall, she added, and look at implementing prevention strategies, as well as exercise programs to increase the strength and balance of residents, and better lighting to prevent trips.

Pharmacist and senior author Dr Nasir Wabe said falls continue to be one of the leading challenges in aged care, but noted there are opportunities to prevent falls through targeted interventions.

"The Australian government has facilitated access to medication review services through initiatives such as embedded pharmacists and the Residential Medication Management Review programs, and providers are encouraged to make the most of these opportunities," Dr Wabe said.

Read the paper [HERE](#). KB

Market jitters for pharma companies

AFTER seemingly escaping US President Donald Trump's reciprocal tariffs, pharmaceutical companies around the world are now bracing for what Trump has called a "major tariff on pharmaceuticals".

"We are going to tariff our pharmaceuticals and once we do that they're going to come rushing back into our country because we're the big market," Trump was reported as saying at a Republican Party fundraiser yesterday.

The US imports large amounts of medicines from India, Europe and China without buyers paying tariffs, thanks to a 1995 WTO agreement aimed at keeping medicines affordable.

Global pharma stocks have dropped across the board in response to the news.

Stocks in major Australian exporter CSL dropped to \$233.62 at close of trading yesterday before rallying to \$244.66 as we went to press.

Trump has not said when and by how much he plans to raise levies on pharma imports.

Given the complexity of the pharma supply chain, some experts have questioned whether the industry would make any major changes, and may simply ride out the current US administration.

Meanwhile, US consumers are likely to bear the brunt of increased costs.

Save time. Save Money.

Time to rethink your dispensary set-up?

The latest in pharmacy robotic automation from Willach Pharmacy Solutions. No matter the size of your pharmacy, contact us for a confidential discussion to explore the options available.



Editor's Choice: The Ordinary's Serum Foundation makes a comeback

THE Ordinary's viral foundation (RRP \$12.70) is back, but only a limited release is available.

Since the skincare brand expanded into cosmetics and launched its Serum Foundation in 2017, then discontinued it five years later, its community has consistently called for its return.

In fact, a 25,000-person waiting list for the popular product quickly grew after the product left the shelves.

The Ordinary's lightweight 30ml Serum Foundation offers a moderate coverage with a real-skin finish and is suitable for all skin types.

With 36 shades, the range is divided into four categories and



four different undertones to help users find their perfect colour.

The Serum Foundation is vegan, free of alcohol, silicon, oil and water and not tested on animals.

Launched in Canada in 2016, The Ordinary is a skincare brand known for its affordable prices and no-nonsense, scientific approach to product formulations.

Natio gets its Glow on



AUSTRALIAN skincare brand Natio has today released its new Glow range, designed to brighten and hydrate the skin.

The new product line-up is formulated with a blend of heatlessly extracted, water soluble antioxidant botanicals including Kakadu plum, pomegranate and goji berry extracts.

"Antioxidants are true skincare superstars," said Natio Product Development Manager Kerith Barnett.

"They help to protect skin against the oxidation damage and accelerated ageing from everyday biological processes and environmental aggressors like UV and pollution.

"They also help to reduce inflammation and optimise skin repair and renewal, boosting skin's overall wellbeing."

Included in the range are the Beauty Boost Cleansing Balm (RRP \$29.95); 24/7 Hydrating Water Cream (RRP \$28.95); Purely Radiant Botanical Face Oil (RRP \$24.95); Brighter Skin Refining Toner (RRP \$19.95); Multi-Action Exfoliating Concentrate (RRP \$26.95); Purely Radiant Botanical Face Oil (RRP \$24.95); and Glow 10 Minute Miracle Mask (RRP \$19.95).

Sexual wellness

POPULAR US brand PlusOne is now available online at Chemist Warehouse Marketplace, offering a curated range of its affordable, sexual wellness products.

According to the PlusOne, the brand is "dedicated to breaking down outdated taboos around self-pleasure and intimacy".



Serum delivers a serious hydration punch



LANA Banana has introduced two serum superstars: The Day Serum and The Night Serum.

Designed to work around the clock, the formulas deliver targeted ingredients to your skin.

The lightweight morning serum

(RRP \$99) is like a green juice for your skin.

Packed with hydrating peptides, antioxidants, and calming actives, it plumps, protects, and preps your complexion for the day ahead.

The night serum (\$99) is your overnight skin support system.

With gentle exfoliants, collagen-boosting peptides, and a nourishing botanical blend, it helps fade dullness, smooth texture and promote overnight regeneration, so you wake up with glowing, non-greasy skin.

To use them, apply one to two pumps after cleansing, followed by moisturiser (and sunscreen for day use).

The brand is looking to retail in pharmacies - for stocking enquiries contact hello@lanabanana.co.

Want to feature on this page?

email advertising@pharmacydaily.com.au to find out more

Beauty & Wellness
by Pharmacy Daily



Dispensary Corner

A PHARMACY customer in the US has taken to social media to complain about their local pharmacy store after it refused to serve them two minutes before closing time.

The disgruntled shopper explained on X that they entered the CVS Pharmacy and stood in line at 4:58pm.

The pharmacist on duty reportedly told the customer that the woman in front of them was the last patient of the day.

"Rolled into CVS Pharmacy yesterday and stood in line at 4:58pm," the customer complained on X.

They noted that the pharmacy shut down at 5pm, but they were unaware of the time.

"Um...I'm in line and you aren't closed yet," recounted the shopper.

"She didn't care."

The company's customer service page replied to the X user, saying they were "sorry to hear about [their] experience".

"Could you please direct message us the location of the CVS pharmacy in question, so we can address your concerns with the appropriate team?"

It is unknown whether or not the customer chose to escalate the situation privately.

A similar incident occurred last month, when another CVS store upset a customer by denying them service at 5:01pm.

The woman was third in the drive-thru line for her daughter's prescription at 4:50pm, but when they reached the window one minute past closing time, they were turned away.

Flooding impacts long-term health

THE world's largest and most comprehensive study of the long-term health impacts of flooding has found a 26% increased risk of diseases serious enough to require hospitalisation.

This impact on the health of communities lasts up to seven months post event, said the study authors, led by Monash University researchers.

The analysis of over 300 million hospitalisation records in eight countries prone to flooding events, including Australia, found that they led to increases in hospitalisation for cardiovascular diseases (35%), respiratory diseases (30%), infectious diseases (26%), digestive diseases (30%) such as gastroenteritis, mental health disorders (11%), diabetes (61%), cancer (34%), nervous system disorders (34%), and renal diseases (40%).

In Australia, where researchers looked at the impact of flooding in northern NSW, the hospitalisation risks of some cause-specific diseases decreased after floods, while risks of other cause-specific diseases increased after floods.

Diabetes-related hospitalisations increased significantly, with respiratory and infectious diseases,

and injuries also higher.

However, mental health hospitalisations were lower.

The authors said this might be because the hospitalisations of some diseases were prioritised after floods, so the hospitalisations of other diseases were delayed and limited in number.

Flood events impact health through the contamination of water supply systems and the growth of fungi, bacteria, viruses, and vectors like mice and insects, which can trigger outbreaks of respiratory, digestive and infectious diseases.

Floods may also force massive evacuations, causing displacement, while temporary shelters may be short in sanitation facilities.

Access and capacity to healthcare services may be impaired after floods, leading to delay in regular medical interventions.

This is the first and most comprehensive study to look at broader impacts on health, suggesting that the health impact of floods may have been underestimated and will further exacerbate as climate changes, the



authors noted.

"Projections indicate an escalation in the severity, duration and frequency of floods due to the more frequent extreme precipitation events and rising sea levels due to global warming," they pointed out.

"Policymakers and health professionals should raise awareness of the increased hospitalisation demands from a broad range of diseases after floods to improve disaster response strategies and health system resilience to optimise the prognosis of the incidence or onset of diseases during and after floods to cope with the health challenges brought by climate change," the authors concluded.

Read the paper [HERE](#). *KB*

Climate change predicted to make allergic rhinitis worse

A REVIEW published in *The Laryngoscope* reports that changes in pollen seasons and concentrations caused by climate change are contributing to increased rates of hay fever.

Studies have reported longer pollen seasons and/or higher pollen concentrations related to climate change, which is expected to get worse over time - total pollen emissions in the US are

projected to increase by 16-40% by the end of the century and the pollen season length expected to increase by 19 days.

They also found evidence of an increase in allergic rhinitis-related health care usage, particularly among low-income residents.

"Our scoping review highlights how climate change is altering pollen seasons and concentrations, AR disease

prevalence, allergy sensitisation, and AR symptom severity," wrote the authors.

"Health professionals are uniquely positioned to witness the impact of allergic rhinitis on patient outcomes and can adapt their practice as climate change intensifies," they noted, adding that health professionals are keen for more education on the impacts of climate change on health.

Do The Math(s)!

Chemsave

10 New Members
in the last 20 weeks

= 1 New Member
every 2 weeks!



YOUR BIG SAVINGS CHEMIST

 **WEALTH
100CLUB**

LOOKING TO BUY
A PHARMACY?

**0% DEPOSIT
100% OWNERSHIP**

BECOME A FREE
CLUB MEMBER TODAY

A CHEMSAVE
INITIATIVE



VIC, SA, WA, TAS & NT

Michael Story
0425 820 160
michaelstory@chemsave.com.au



NSW, QLD & ACT

Simon Metcalfe
0499 208 182
simonmetcalfe@chemsave.com.au